In contrast, there was no difference in overall survival between the 19q-loss GBM and 19q-intact GBM (P = .4). In a case of 19q-loss AA, both oligodendroglial morphology and 19q-loss disappeared after recurrence, possibly indicating correlation between 19q-loss and oligodendroglial morphology. We showed that there was a subgroup, although small, of IDH-mutated astrocytomas harboring 19q-loss that present oligodendroglial morphology, and also were associated with significantly better prognosis compared to other 19q-intact astrocytomas.
with clinical information. However, accumulation of information on molecular alterations of gliomas has been changing this process significantly over the past 20- In a previous study comparing the histological features and molecular genetics, we noticed that there was relatively small number of cases of non-codeleted diffuse gliomas presenting oligodendroglial morphological features, and those tend to have 19q-loss only. 5 In this study, we investigated those tumors further, including morphology, other genetic alterations, and clinical prognosis. 
| MATERIALS AND METHODS

| Patients
| DNA extraction
The tumor samples were frozen in liquid nitrogen immediately after resection and stored at À80°C until use. DNA from the tumor tissue was extracted using the QIAamp DNA Mini Kit (Qiagen, Valencia, CA, USA) following the manufacturer's protocol. Constitutional DNA used as a control was extracted from peripheral blood.
Written informed consent was obtained from all patients involved. All experiments using human samples were approved by the ethics committee at the Dokkyo Medical University (Nos. 1431 and 24053).
| Microsatellite analysis
Microsatellite analysis was undertaken using the Genetic Analyzer 
| The Cancer Genome Atlas data
The clinical, mutation, and copy number variation data of 516 cases from the Brain Lower Grade Glioma project were obtained from The
Cancer Genome Atlas (TCGA) datasets using the cBioPortal (http:// www.cbioportal.org). The 1p/19q status was determined by downloading the copy number data, and cases with <À0.3 log 2 value of mean copy number of either 1p or 19q were scored as 1p-loss or 19q-loss, respectively. Only cases with loss of the long arm of chromosome 19 without loss of the short arm of chromosome 1 were considered as 19q-loss astrocytomas.
| Statistical analysis
The log-rank test was used to compare OS. and ATRX mutation was detected in 2/7 (29%). However, TERT promotor mutation, CIC mutation or FUBP1 mutation was not detected in any of the seven tumors (Table 2 ). These results confirmed that those tumors were molecular genetically compatible with the diagnosis of astrocytomas. No other genes commonly mutated in gliomas were detected, except that mutation of SMARCB1, MSH6, and LRP1B
were detected in case 1, and mutation of PIK3CA was detected in case 7.
| Morphological change accompanied with loss of 19q-loss at recurrence
In one case (case 3), we could obtain samples at recurrence. This patient was a 40-year-old man with a left frontal glioma. Primary tumor was IDH-mutated, 1p-intact/19q-loss AA with oligodendroglioma-like regions and neuropil-like islands. There was a TP53 mutation, but no TERT promotor mutation. After gross total resection, the patient underwent radiation therapy (60 Gy) with temozolomide, and the tumor recurred after 2 years. The recurrent tumor was resected again, and molecular examination showed that the IDH1 mutation and TP53 mutation were maintained, but the 19q-loss was not observed ( Figure 4A) . Notably, the oligodendroglioma-like morphology observed in the primary tumor was not evident in the recurrent tumor ( Figure 4B ). This case suggested that there might be an association between the oligodendroglial morphology and 19q-loss.
| Validation analysis on TCGA dataset
Of the 516 cases included in the Brain Lower Glioma project in TCGA datasets, 228 cases with both IDH mutation and TP53 Cytogenetic studies revealed that unbalanced translocation between chromosome 1 and 19 resulting in the loss of der(1;19)(p10;q10) was the mechanism of the codeletion. 10 However, despite extensive past efforts looking for specific genes primarily targeted by 1p-loss and 19q-loss in oligodendrogliomas, those genes have not been pinpointed. Analysis of commonly deleted regions of 19q in astrocytoma had narrowed the region to 19q13.3, but none of the candidate genes within this region showed constant mutation. Although the 19-loss-only astrocytomas appear to constitute only <10% of lower grade astrocytomas, and hence pose limitations to our study, the validation study on the independent TCGA dataset was in line with our notion.
In conclusion, we showed that there appears to be a subgroup of IDH-mutated astrocytomas harboring 19q-loss and TP53 mutation, which can present morphology similar to oligodendroglial tumors, and also show significantly better prognosis compared to 
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